The FDA has accepted a supplemental biologics license application (sBLA) for the use of pembrolizumab (Keytruda) as an adjuvant treatment for patients with resected, high-risk stage III melanoma, according to Merck (MSD), the manufacturer of the PD-1 inhibitor.
= .0009). The 18-month RFS rates were 69.2% versus 52.4%, respectively.
Among BRAF wild-type patients, the 1-year RFS rate was 73.0% with pembrolizumab versus 59.7% with placebo (HR, 0.64; 99% CI, 0.42-0.96; P = .0039). The 18-month RFS rates were 66.7% versus 48.8%, respectively.
... to read the full story